美国食品药品监督管理局（FDA）已确认，Cardiamp HF II临床试验的结果，可能为BioCardia公司旗下Cardiamp细胞疗法用于治疗缺血性心力衰竭伴射血分数降低（HFrEF）的上市前批准（PMA）申请提供支持性数据。这一积极反馈标志着该创新疗法在监管审批路径上的关键进展，为后续正式提交PMA奠定了重要基础。
美国食品药品监督管理局（FDA）已确认，Cardiamp HF II临床试验的结果，可能为BioCardia公司旗下Cardiamp细胞疗法用于治疗缺血性心力衰竭伴射血分数降低（HFrEF）的上市前批准（PMA）申请提供支持性数据。这一积极反馈标志着该创新疗法在监管审批路径上的关键进展，为后续正式提交PMA奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.